Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posttransplant cyclophosphamide and tacrolimus for GVHD prevention after HLA-matched allo-HCT
jRCTs051180143Phase 2Completed
- Start
- Oct 2016
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and tacrolimus in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute leukemia of ambiguous lineage (ALAL) and 4 more. Primary endpoint: 1-year chronic GVHD cumulative incidence. Started Oct 2016; status: completed.
02
Drugs
cyclophosphamidetacrolimus
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs051180143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180143.